News Release

Linking infectious and narcology care is effective in suppressing HIV in people who inject drugs in Russia

Peer-Reviewed Publication

Boston Medical Center

BOSTON – New research from Boston Medical Center found that providing pragmatic support, specifically rapid access to antiretroviral therapy, pharmacotherapy for opioid use disorder, and strengths-based case management, improved treatment outcomes for people with HIV who inject drugs in St. Petersburg, Russia. Published in The Lancet HIV, researchers from the Linking Infectious and Narcology Care – Part II (LINC-II) trial highlight that the odds of achieving viral load suppression at 12 months are 3 times higher for participants randomized to the intervention group.

Russia continues to have the largest HIV epidemic in Europe, with the total number of people with HIV exceeding 1.4 million and over 71,000 new infections in 2021. Among the newly diagnosed Russian people with HIV in 2021, 28% reported past injection drug use. Strengthening the HIV response in Russia requires engaging people who inject drugs in treatment. Antiretroviral therapy coverage in Russia is low for people with HIV who inject drugs, and HIV and addiction treatment in Russia are not well integrated.

While the study’s focus was on people with HIV who inject drugs in St. Petersburg, Russia, the implications of early ART initiation extend far beyond national borders.

“We hope to improve the treatment for people with HIV who inject drugs by addressing barriers for accessing both HIV and addiction care, a challenge both in Russia and other countries with this population,” said senior author Jeffrey Samet, MD, MA, MPH, a primary care physician at Boston Medical Center and John Noble, M.D. Professor in General Internal Medicine at Boston University Chobanian & Avedisian School of Medicine. “Scaling up the LINC-II model is one strategy to advance the UNAIDS goal of ending the HIV epidemic.”

These findings support the usefulness of expanding the LINC-II approach in Russia, given both the positive outcomes of the findings and the high receptivity by participants to elements of the intervention.

Researchers believe that although significant improvements were achieved with the intervention, the results do highlight the great challenge of effectively treating people with HIV who inject drugs.


Research reported in this press release was supported by the National Institute on Drug Abuse of the National Institutes of Health under award number R01DA045547.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.



About Boston Medical Center

Boston Medical Center models a new kind of excellence in healthcare, where innovative and equitable care empowers all patients to thrive. We combine world-class clinicians, cutting-edge treatments, and advanced technology with compassionate, quality care, that extends beyond our walls. As an award-winning health equity leader, our diverse clinicians and staff interrogate racial disparities in care and partner with our community to dismantle systemic inequities. And as a national leader in research and the teaching affiliate for Boston University Chobanian & Avedisian School of Medicine, we’re driving the future of care.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.